Alex Mabry

Program: Cancer Biology

Current advisor: Jason D. Weber, PhD

Undergraduate university: Indiana University-Bloomington, 2018

Enrollment year: 2021

Research summary
Therapeutic targeting of type I interferon signaling in CDK4/6i resistant ER+/HER2- breast cancer

Graduate publications
Kong T, Mabry A, Highkin M, Wang AZ, Hoog J, Guo Z, Gonzales-Gonzales A, Thomas S, Song Y, Gao F, Opyrchal M, Peterson L, Ademuyiwa F, Margenthaler J, Aft R, Glover-Collins K, Nehring L, Tao Y, Sanati S, Hagemann IS, Boulos F, Holt M, Ding L, Zhu W, Oh ST, Wang J, Witkiewicz AK, Knudsen ES, Bose R, Weber JD, Goetz M, Northfelt D, Luo J, Ma CX
Kong T, Mabry A, Highkin M, Wang AZ, Hoog J, Guo Z, Gonzales-Gonzales A, Thomas S, Song Y, Gao F, Opyrchal M, Peterson L, Ademuyiwa F, Margenthaler J, Aft R, Glover-Collins K, Nehring L, Tao Y, Sanati S, Hagemann IS, Boulos F, Holt M, Ding L, Zhu W, Oh ST, Wang J, Witkiewicz AK, Knudsen ES, Bose R, Weber JD, Goetz M, Northfelt D, Luo J, Ma CX. 2026 Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial. Nat Commun, 17(1):949. PMCID: PMC12848104

Mabry A, Kuzmicki CE, O’Brien A, Maggi LB Jr, Weber JD. 2025 Elevated Type I Interferon Signaling Defines the Proliferative Advantage of ARF and p53 Mutant Tumor Cells. Mol Cell Biol, 45(6):246-61. PMCID: PMC12136988

Panikar SS, Keltee N, Berry NK, Shmuel S, Fisher ZT, Brown E, Zidel A, Mabry A, Pereira PMR. 2023 Metformin-Induced Receptor Turnover Alters Antibody Accumulation in HER-Expressing Tumors. J Nucl Med, 64(8):1195-202. PMCID: PMC10394312